GlassScriptPhysician profile
Amy J Hunt
NPI 1447785084
$1,737.92
in general payments reported to CMS, 2019-2025
34 companies · $236 in 2025
The $236 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $294 · 2022: $364 · 2023: $606 · 2024: $238 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,021 · Consulting Fee: $60.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,020.51 |
| Consulting Fee | $60.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $192.31 | 2022-2024 | Enhertu, Injectafer |
| Alexion Pharmaceuticals, INC. | $150.00 | 2021 | |
| Abbvie INC. | $117.26 | 2022-2025 | |
| Amgen INC. | $103.27 | 2021-2023 | Lumakras |
| Lilly USA, LLC | $83.55 | 2021-2024 | Retevmo, Jaypirca, Verzenio |
| Janssen Biotech, INC. | $82.27 | 2021-2024 | Rybrevant |
| Pharmacosmos Therapeutics INC. | $81.07 | 2022-2023 | Monoferric |
| Astrazeneca Pharmaceuticals LP | $76.52 | 2022-2025 | Imjudo, Tagrisso |
| Bayer Healthcare Pharmaceuticals INC. | $75.26 | 2022-2023 | |
| Taiho Oncology, INC. | $66.70 | 2023-2025 | |
| Incyte Corporation | $61.73 | 2021-2024 | Jakafi |
| Merck Sharp & Dohme LLC | $61.16 | 2021-2025 | Keytruda |
| Biogen, INC. | $60.00 | 2023 | Tysabri |
| Pfizer INC. | $46.85 | 2022-2024 | |
| Genzyme Corporation | $41.92 | 2022-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $37.82 | 2022 | |
| Intuitive Surgical, INC. | $33.53 | 2025 | |
| Mirati Therapeutics, INC. | $32.09 | 2023 | Krazati |
| Genentech USA, INC. | $30.61 | 2022-2024 | Tecentriq |
| Regeneron Healthcare Solutions, INC. | $27.88 | 2023 | Libtayo |
| Novartis Pharmaceuticals Corporation | $24.60 | 2025 | |
| Pharmaessentia USA Corporation | $24.28 | 2023 | Besremi |
| Janssen Pharmaceuticals, INC | $23.90 | 2024 | Xarelto |
| Ipsen Biopharmaceuticals, INC | $21.87 | 2022 | |
| Astellas Pharma US INC | $21.68 | 2023 | Padcev |
| Jazz Pharmaceuticals INC. | $20.29 | 2022 | |
| Genmab U.S., INC. | $20.27 | 2023 | Epkinly |
| Glaxosmithkline, LLC. | $18.63 | 2024 | Ojjaara |
| Stemline Therapeutics INC. | $17.73 | 2025 | Elzonris |
| Pharmacyclics LLC, An Abbvie Company | $17.47 | 2023 | Imbruvica |
| Array Biopharma INC | $16.99 | 2025 | Braftovi, Mektovi |
| Apellis Pharmaceuticals, INC. | $16.87 | 2025 | Empaveli |
| Takeda Pharmaceuticals U.S.A., INC. | $16.53 | 2023 | Ninlaro |
| Mylan Institutional INC. | $15.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Hunt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.